Galenica AG Stock Deutsche Boerse AG

Equities

G70

CH0360674466

Pharmaceuticals

Delayed Deutsche Boerse AG 09:43:43 2019-06-28 EDT 5-day change 1st Jan Change
43.98 EUR -0.50% Intraday chart for Galenica AG -.--% -.--%

Financials

Sales 2024 * 3.92B 4.37B 4.05B 6.01B Sales 2025 * 4.08B 4.55B 4.21B 6.25B Capitalization 3.73B 4.16B 3.85B 5.72B
Net income 2024 * 174M 194M 180M 267M Net income 2025 * 183M 204M 189M 281M EV / Sales 2024 * 1.09 x
Net Debt 2024 * 540M 602M 557M 828M Net Debt 2025 * 510M 569M 526M 782M EV / Sales 2025 * 1.04 x
P/E ratio 2024 *
21.6 x
P/E ratio 2025 *
20.4 x
Employees 6,181
Yield 2024 *
3.05%
Yield 2025 *
3.16%
Free-Float 99.44%
More Fundamentals * Assessed data
Dynamic Chart
5 years
43.88
Extreme 43.88
45.52
10 years
37.82
Extreme 37.82
52.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 -
Director of Finance/CFO 58 09-12-31
Chief Tech/Sci/R&D Officer 52 21-12-31
Members of the board TitleAgeSince
Chief Executive Officer 71 95-12-31
Director/Board Member 66 23-05-10
Director/Board Member 62 16-12-31
More insiders
Galenica AG, previously Galenica Sante Ltd, is a Switzerland-based healthcare services and products provider. The Company's business i divided into three business sectors: Retail, Products & Brands, and Services. The Company manages a locally established pharmacies network in Switzerland. It develops and distributes its own product portfolio, as well as cooperates with a range of business partners, such as Pierre Fabre, Ales Groupe and Vitor Consumer Health for marketing and distribution of such brands as Perskindol, Triofan, A-Derma, Lierac, Phyto, Anti-Brumm and Algifor. Galenica Sante's Services business sector is responsible for management of such logistics sector companies as Galexis, Unione Farmaceutica Distribuzione, Alloga and Medifilm.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
74.9 CHF
Average target price
77 CHF
Spread / Average Target
+2.80%
Consensus